Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various
receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib …

Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC
subtypes, commonly impacts younger patients, and is often metastatic at presentation …

Papillary renal cell carcinoma (pRCC) is the second most frequent renal cell carcinoma
(RCC) after clear cell RCC. In contrast to clear cell RCC, there is no consensual protocol …

Purpose To compare revised Choi criteria that incorporate concurrent size and attenuation
changes at early follow-up imaging with Response Evaluation Criteria in Solid Tumors …

Collecting duct carcinomas (CDCs) are a particularly rare subtype of kidney cancer,
endowed by a particularly poor prognosis. Since no active treatments have been …

Simple Summary Non-clear cell renal cell carcinoma (nccRCC) represents about the 20% of
all RCCs but recommendations on treatment lacks evidence since the clinical trials include …

The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant
renal carcinomas. Each subtype harbors a distinct cell of origin and exhibits a distinct clinical …

Non–clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases
with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence and …

Background The randomized phase III trial of sunitinib versus interferon Alfa provided level-
A evidence for the use of sunitinib in advanced clear cell renal cell carcinoma (RCC). This …

Aim This study evaluated the safety and efficacy of sunitinib in the treatment of advanced
non‐clear cell renal cell carcinoma. Methods Thirty‐seven C hinese patients with advanced …